ArticleThe Journal of antibiotics2026
Comprehensive derivatization of thiostrepton via heterologous expression.
Article in The Journal of antibiotics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
New technology for the derivatization of thioamide ribosomally synthesized and post-translationally modified peptide (RiPP) compounds we previously developed was optimized for the derivatization of thiostrepton metabolites. These optimized procedures allowed for efficient thiostrepton derivatization. A heterologous expression system using an engineered Streptomyces avermitilis strain also exhibited high performance for metabolite production. We developed a streamlined procedure to generate new thiostrepton derivatives and apply their antimicrobial activities against gram-positive bacteria. Heterologous expression of 27 constructs with amino acid substitution mutation(s) in an engineered S. avermitilis strain produced 20 designed thiostrepton derivatives along with several previously undescribed analogs. Derivatives in which the second or fourth Ala residue in the thiostrepton skeleton was replaced with Ser or Val, respectively, exhibited improved antibacterial activity. The data suggest the present strategy is suitable for generating novel non-natural metabolites. Thiostrepton can induce expression of the tipA promoter of Streptomyces lividans 1326. It is highly intriguing that the antimicrobial activity of thiostrepton and its derivatives is correlated with induction of the tipA promoter.
Indexed as
Identifiers
42521744What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.